10262-69-8 Usage
Originator
Maprotiline hydrochloride ,Mylan
Uses
Different sources of media describe the Uses of 10262-69-8 differently. You can refer to the following data:
1. Maprotiline disrupts neuronal reuptake of monoamines in the CNS and possesses moderate tranquilizing and cholinergic activity. It improves mood significantly and relieves feelings of
fear. Maprotiline is used in various forms of depression accompanied by a feeling of fear
and irritability.
2. Antidepressant.
Manufacturing Process
9-(3-Hydroxypropyl)anthracene was prepared by reduction of 3-(9-anthryl) propionic acid with LiAlH4. By action of thionylchloride and then methylamine the 9-(3-hydroxypropyl)anthracene was converted to 9-(3-methylaminopropyl) anthracene. By addition of ethylene to 9-(3-methylaminopropyl)anthracene (at 150°C, a pressure of ethylene 50 atm, 24 hours) was obtained 3-(9,10- dihydro-9,10-ethanoanthracene-9-yl)-N-methylpropylamine. Hydrochloride 3- (9,10-dihydro-9,10-ethanoanthracene-9-yl)-N-methylpropylamine may be prepared by action hydrochloric acid.
Therapeutic Function
Antidepressant
Mechanism of action
Maprotiline is slowly but completely absorbed from the GI tract, and like the other TCAs, it is metabolized by
the polymorphic CYP2D6 and CYP2C19 isoforms in the liver, primarily to pharmacologically active
N-desmethylmaprotiline and to maprotiline-N-oxide.Maprotiline
is distributed into breast milk at concentrations similar to those found at steady state in maternal blood. The
elimination half-life of maprotiline averages 43 hours (60–90 hours for its N-desmethyl metabolite).Maprotiline shares the toxic potentials of the TCAs, and the usual precautions of TCA administration should
be observed.
Clinical Use
Maprotiline is a secondary amine dibenzobicyclooctadiene (a tetracyclic antidepressant) that differs
structurally from the TCAs by having an ethylene bridge in its central ring, resulting in a rigid bicyclomolecular skeleton .
Maprotiline exhibits the highest affinity and selectivity for the NE transporter. Its antidepressant
mechanism of action is similar to that of desipramine, with an onset of action of up to 2 to 3 weeks.
Side effects
Although most of the TCAs have been reported to induce seizures, it is generally recognized that maprotiline may be associated with a higher
incidence of dose-dependent seizures compared with the other secondary TCAs. Maprotiline has been
reported to produce sedation in depressed patients and to reduce aggressive behavior in animals. Maprotiline
also shares the anticholinergic and cardiovascular effects of the secondary TCAs and may cause
electrocardiographic changes, tachycardia, and postural hypotension.
Synthesis
Maprotiline, N-methyl-9,10-ethanoanthracen-9(10H)-propylamine (7.1.22), is
synthesized by a 42 cycloaddition reaction of 9-(3-methylaminopropyl)anthracene with
ethylene [39–41].Maprotiline is frequently referred to as a tetracyclic antidepressant. This “hybrid” drug,
containing both elements of “classic tricyclic antidepressants” and protriptyline elements,
is pharmacologically and clinically more similar to imipramine.
Check Digit Verification of cas no
The CAS Registry Mumber 10262-69-8 includes 8 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 5 digits, 1,0,2,6 and 2 respectively; the second part has 2 digits, 6 and 9 respectively.
Calculate Digit Verification of CAS Registry Number 10262-69:
(7*1)+(6*0)+(5*2)+(4*6)+(3*2)+(2*6)+(1*9)=68
68 % 10 = 8
So 10262-69-8 is a valid CAS Registry Number.
InChI:InChI=1/C20H23N/c1-21-14-6-12-20-13-11-15(16-7-2-4-9-18(16)20)17-8-3-5-10-19(17)20/h2-5,7-10,15,21H,6,11-14H2,1H3
10262-69-8Relevant articles and documents
Combination of adrenergic agonist and tricyclo-alkylamine for relieving chronic pain without adverse side effects
-
, (2008/06/13)
This invention discloses that a combination of two drugs, from two different and previously unrelated categories, provides effective and long-lasting relief from neuropathic pain. Both drugs can be taken orally, in a convenient, painless, non-invasive manner that does not require injections. One drug in this combination is an α2 adrenergic agonist, exemplified by clonidine. The other drug in the pain-relieving combination has a tri-cyclo-alkyl-amine (TCAA) structure. At least some TCAA drugs have antagonist (receptor-blocking) activity at two entirely different classes of neuronal receptors: the muscarinic subclass of acetylcholine (ACh) receptors, and the NMDA subclass of glutamate receptors. Such drugs include ethopropazine, normally used as an anti-cholinergic drug, and desipramine, normally used as an anti-depressant. Tests by the Applicants have shown that at least some TCAA drugs can relieve neuropathic pain to a limited extent, but at the doses required to relieve pain, they cause adverse side effects, and any pain relief is relatively brief and short-lived. However, when a TCAA drug such as ethopropazine is administered together with an α2 adrenergic agonist such as clonidine, these drugs mutually potentiate one another's neuropathic pain-relieving action, and provide potent and sustained neuropathic pain relief, even when each agent is administered at a low dosage that is below its threshold for causing adverse side effects. Accordingly, this drug combination can provide safe and effective relief of neuropathic pain and possibly other types of chronic and/or intractable pain, at dosages which are so low that they do not pose serious risks of adverse side effects.
